Gene Therapy on Cardiovascular Disease Market Surges With Clinical Success and 67.4 Percent CAGR Highlighting Massive Industry Potential

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Gene Therapy on Cardiovascular Disease Market - (By Type (Viral Gene Therapy, Non-Viral Gene Therapy), By Application (Heart Disease, Vascular Disease)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Gene Therapy on Cardiovascular Disease Market is predicted to grow with a CAGR of 67.4% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2451

Gene therapy for cardiovascular diseases, particularly coronary artery disease, involves the introduction of genetic material into a patient's cells to treat or prevent pathological conditions. The primary objective of this therapeutic approach is to improve cardiac and vascular function by correcting genetic abnormalities or modulating gene expression. Viral vectors are commonly utilized as delivery systems for transporting therapeutic genes into cardiac and vascular tissues. Clinical studies have demonstrated promising outcomes, including improved cardiac performance in cases of heart failure and inherited cardiovascular disorders. As research and development activities in this domain continue to expand, interest from both public institutions and private investors is intensifying, thereby fostering growth in the gene therapy market targeting coronary artery disease.

In parallel with traditional gene therapies, mRNA-based therapeutics are gaining traction as a novel and innovative treatment modality. These therapies function by delivering synthetic messenger RNA to target cells, prompting the cellular machinery to produce specific therapeutic proteins. This approach offers several benefits, including enhanced safety profiles, lower production costs, and expedited manufacturing timelines when compared to conventional gene therapies.

Despite these advancements, the market faces a significant challenge in the form of talent retention. The specialized expertise required in gene therapy research and clinical application is in high demand, and the ongoing shortage of qualified professionals presents a critical obstacle to sustaining long-term growth and operational efficiency in this rapidly evolving sector.

List of Prominent Players in the Gene Therapy on Cardiovascular Disease Market:
• Biogen
• Novartis
• Gilead Sciences
• Sarepta Therapeutics
• Alnylam Pharmaceuticals
• Amgen
• Spark Therapeutics
• Akcea Therapeutics
• Sunway Biotech
• bluebird bio
• SIBIONO
• AnGes
• Orchard Therapeutics
• Other Market Players

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The growing demand for gene therapy in the cardiovascular disease market is largely attributed to the increasing prevalence of chronic conditions, such as cancer and rare genetic disorders. As gene therapy continues to gain recognition as a viable and innovative treatment modality-particularly in oncology-its application in cardiovascular care is expanding. This momentum is further supported by rising governmental funding and supportive policy initiatives, collectively driving the adoption and development of gene therapy solutions within the cardiovascular disease landscape.

Challenges:
Despite its potential, the market faces several constraints. High capital investment requirements, a limited pool of skilled professionals, and the absence of standardized clinical protocols-particularly in emerging markets-pose significant challenges. These issues are exacerbated by delayed regulatory approvals, often stemming from the impact of COVID-19-related lockdowns and supply chain disruptions. Moreover, the elevated costs associated with gene therapy development and administration are often transferred to patients, limiting accessibility for individuals without comprehensive insurance coverage. The lack of established reimbursement models and restricted insurer participation, especially in therapies for rare conditions, further hampers market penetration. Concerns regarding long-term efficacy and safety also contribute to payer hesitancy, collectively slowing the broader adoption of gene therapy in cardiovascular medicine.

Regional Trends:
North America is expected to dominate the gene therapy market for cardiovascular diseases, driven by a high incidence of cardiovascular conditions, substantial investment in research and development, rapid technological innovation, and favorable government initiatives. Rising healthcare expenditure also supports continued growth in this region. Europe is similarly witnessing robust market expansion, supported by a sizable patient base, heightened public awareness, increased research activity, and a relatively high prevalence of cancer and infectious diseases. These factors collectively position both North America and Europe as key contributors to the global growth of gene therapy in cardiovascular healthcare.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2451

Recent Developments:
• In Nov 2023, Amgen presented new information at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, which further supports the safety and effectiveness of Repatha® (evolocumab) based on the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial. The presentations will specifically address the reduction of LDL "bad" cholesterol (LDL-C), which is a well-known risk factor for cardiovascular disease (CVD).
• In Aug 2023, Lexeo Therapeutics received a strategic investment from Sarepta Therapeutics to aid in the advancement of Lexeo's cardiovascular gene therapies. The companies will investigate the creation of innovative gene therapy candidates for various cardiovascular diseases as part of this investment.

Segmentation of Gene Therapy on Cardiovascular Disease Market-
By Type-
• Viral Gene Therapy
• Non-Viral Gene Therapy
By Application-
• Heart Disease
• Vascular Disease
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/gene-therapy-on-cardiovascular-disease-market/2451

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.